See highlights from the Global Science Summit

Current Pipeline
CRISPR

UNC

University of North Carolina (UNC) is exploring an investigational viral delivered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CAS9 approach to treating Angelman syndrome.

Discovery & DevPre-clinicalPhase 1Phase 2Phase 3To Patients

About the Program

A gene editing tool that utilizes a guide RNA (gRNA) to recognize a specific section of DNA or RNA and directs an enzyme (nuclease) to cut at a specific section in the DNA or RNA. Designing a CRISPR that affects the UBE3A-ATS could potentially allow the paternal UBE3A gene to be turned on. It could also be used to edit a mutation in a gene, known as base editing.

Company Website
Zylka Lab

Program News

Bench to bedside, Carolina leads study of Angelman syndrome

Read More

Home / News / Scientists Take Major Step Toward Angelman Syndrome Gene Therapy Scientists Take Major Step Toward Angelman Syndrome Gene Therapy

Read More

Zylka Lab awarded $6.1 million from NIH to develop CRISPR/Cas9 gene therapy for Angelman syndrome, study UBE3A autism gene with Philpot Lab

Read More

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.